Cryptococcosis Therapeutic and Drug Pipeline Review H2

Global Cryptococcosis Drugs and Companies Pipeline Review H2 2017

PUNE, INDIA, August 14, 2017 /EINPresswire.com/ — Pune, India, 14th August 2017: WiseGuyReports announced addition of new report, titled “Cryptococcosis – Pipeline Review, H2 2017”.

Summary
Cryptococcosis is infection caused by Cryptococcus neoformans fungus. Symptoms include cough, fatigue, fever, head ache, nausea and skin rashes. Predisposing factors are most often seen in people with a weakened immune system, such as those with HIV infection, taking high doses of corticosteroid medications, cancer chemotherapy, or who have Hodgkin's disease. Treatment includes anti fungal drugs.

GET SAMPLE REPORT @ https://www.wiseguyreports.com/sample-request/1705795-cryptococcosis-pipeline-review-h2-2017

Report Highlights
Pharmaceutical and Healthcare latest pipeline guide Cryptococcosis – Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Cryptococcosis (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Cryptococcosis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Cryptococcosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Preclinical stages are 3 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively.

Cryptococcosis (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope
– The pipeline guide provides a snapshot of the global therapeutic landscape of Cryptococcosis (Infectious Disease).
– The pipeline guide reviews pipeline therapeutics for Cryptococcosis (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
– The pipeline guide reviews key companies involved in Cryptococcosis (Infectious Disease) therapeutics and enlists all their major and minor projects.
– The pipeline guide evaluates Cryptococcosis (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
– The pipeline guide reviews latest news related to pipeline therapeutics for Cryptococcosis (Infectious Disease)

Reasons to buy
– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
– Find and recognize significant and varied types of therapeutics under development for Cryptococcosis (Infectious Disease).
– Classify potential new clients or partners in the target demographic.
– Develop tactical initiatives by understanding the focus areas of leading companies.
– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
– Formulate corrective measures for pipeline projects by understanding Cryptococcosis (Infectious Disease) pipeline depth and focus of Indication therapeutics.
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Content: Key Points
List of Tables
List of Figures
Introduction
Cryptococcosis – Overview
Cryptococcosis – Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Cryptococcosis – Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Cryptococcosis – Companies Involved in Therapeutics Development
Arno Therapeutics Inc
Novabiotics Ltd
Visterra Inc
Cryptococcosis – Drug Profiles
AR-12 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NP-339 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule for Fungal Infections – Drug Profile
Product Description
…Continued

ACCESS REPORT @ https://www.wiseguyreports.com/reports/1705795-cryptococcosis-pipeline-review-h2-2017

Get in touch:
LinkedIn: www.linkedin.com/company/4828928
Twitter: https://twitter.com/WiseGuyReports
Facebook: https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts

Norah Trent
wiseguyreports
+1 646 845 9349 / +44 208 133 9349
email us here


Source: EIN Presswire

Arrhythmias Pharmaceutical and Healthcare Pipeline Review H2

Arrhythmias Treatment Pipeline Review H2 2017

PUNE, INDIA, August 14, 2017 /EINPresswire.com/ — Pune, India, 14thAugust 2017: WiseGuyReports announced addition of new report, titled “Arrhythmias – Pipeline Review, H2 2017”.

Summary
An arrhythmia is a problem with the rate or rhythm of the heartbeat. During an arrhythmia, the heart can beat too fast, too slow, or with an irregular rhythm. Signs and symptoms include anxiety, weakness, dizziness, and light-headedness, fainting or nearly fainting, sweating, shortness of breath and chest pain. Treatment includes anti-arrhythmics and anticoagulants.

GET SAMPLE REPORT @ https://www.wiseguyreports.com/sample-request/1705796-arrhythmias-pipeline-review-h2-2017

Report Highlights
Pharmaceutical and Healthcare latest pipeline guide Arrhythmias – Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Arrhythmias (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Arrhythmias (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Arrhythmias and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase I, Preclinical and Discovery stages are 1, 1, 9 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 4 and 1 molecules, respectively.

Arrhythmias (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope
– The pipeline guide provides a snapshot of the global therapeutic landscape of Arrhythmias (Cardiovascular).
– The pipeline guide reviews pipeline therapeutics for Arrhythmias (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
– The pipeline guide reviews key companies involved in Arrhythmias (Cardiovascular) therapeutics and enlists all their major and minor projects.
– The pipeline guide evaluates Arrhythmias (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
– The pipeline guide reviews latest news related to pipeline therapeutics for Arrhythmias (Cardiovascular)

Reasons to buy
– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
– Find and recognize significant and varied types of therapeutics under development for Arrhythmias (Cardiovascular).
– Classify potential new clients or partners in the target demographic.
– Develop tactical initiatives by understanding the focus areas of leading companies.
– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
– Formulate corrective measures for pipeline projects by understanding Arrhythmias (Cardiovascular) pipeline depth and focus of Indication therapeutics.
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Content: Key Points
List of Tables
List of Figures
Introduction
Arrhythmias – Overview
Arrhythmias – Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Arrhythmias – Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Arrhythmias – Companies Involved in Therapeutics Development
Cynata Therapeutics Ltd
Gilead Sciences Inc
LATITUDE Pharmaceuticals Inc
Ono Pharmaceutical Co Ltd
Orion Oyj
SignPath Pharma Inc
Arrhythmias – Drug Profiles
amiodarone – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Antisense Oligonucleotides to Activate hERG1 for Long-QT Syndrome – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
efsevin – Drug Profile
Product Description
Mechanism Of Action
…Continued

ACCESS REPORT @ https://www.wiseguyreports.com/reports/1705796-arrhythmias-pipeline-review-h2-2017

Get in touch:
LinkedIn: www.linkedin.com/company/4828928
Twitter: https://twitter.com/WiseGuyReports
Facebook: https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts

Norah Trent
wiseguyreports
+1 646 845 9349 / +44 208 133 9349
email us here


Source: EIN Presswire

Atrial Fibrillation Therapeutic and Drug Pipeline Review H2

Atrial Fibrillation Treatment Pipeline Review H2 2017

PUNE, INDIA, August 14, 2017 /EINPresswire.com/ — Pune, India, 14thAugust 2017: WiseGuyReports announced addition of new report, titled “Atrial Fibrillation – Pipeline Review, H2 2017”.

Summary
Atrial fibrillation is an irregular and often rapid heart rate that commonly causes poor blood flow to the body. Symptoms include decreased blood pressure, weakness, lightheadedness, confusion and chest pain. The predisposing factors include age, heart disease, high blood pressure, family history and drinking alcohol. Treatments for atrial fibrillation may include medications and surgery.

GET SAMPLE REPORT @ https://www.wiseguyreports.com/sample-request/1705797-atrial-fibrillation-pipeline-review-h2-2017

Report Highlights
Pharmaceutical and Healthcare latest pipeline guide Atrial Fibrillation – Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Atrial Fibrillation (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Atrial Fibrillation (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Atrial Fibrillation and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 3, 2, 8 and 2 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 2 and 1 molecules, respectively.

Atrial Fibrillation (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope
– The pipeline guide provides a snapshot of the global therapeutic landscape of Atrial Fibrillation (Cardiovascular).
– The pipeline guide reviews pipeline therapeutics for Atrial Fibrillation (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
– The pipeline guide reviews key companies involved in Atrial Fibrillation (Cardiovascular) therapeutics and enlists all their major and minor projects.
– The pipeline guide evaluates Atrial Fibrillation (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
– The pipeline guide reviews latest news related to pipeline therapeutics for Atrial Fibrillation (Cardiovascular)

Reasons to buy
– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
– Find and recognize significant and varied types of therapeutics under development for Atrial Fibrillation (Cardiovascular).
– Classify potential new clients or partners in the target demographic.
– Develop tactical initiatives by understanding the focus areas of leading companies.
– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
– Formulate corrective measures for pipeline projects by understanding Atrial Fibrillation (Cardiovascular) pipeline depth and focus of Indication therapeutics.
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Content: Key Points
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Atrial Fibrillation – Overview 6
Atrial Fibrillation – Therapeutics Development 7
Pipeline Overview 7
Pipeline by Companies 8
Pipeline by Universities/Institutes 9
Products under Development by Companies 10
Products under Development by Universities/Institutes 11
Atrial Fibrillation – Therapeutics Assessment 12
Assessment by Target 12
Assessment by Mechanism of Action 14
Assessment by Route of Administration 16
Assessment by Molecule Type 18
Atrial Fibrillation – Companies Involved in Therapeutics Development 20
Acesion Pharma Aps 20
ARCA biopharma Inc 20
Armetheon Inc 21
AstraZeneca Plc 21
Bristol-Myers Squibb Company 22
Cardiome Pharma Corp 22
Daiichi Sankyo Company Ltd 23
Dong-A Socio Holdings Co Ltd 23
Gilead Sciences Inc 24
InCarda Therapeutics Inc 24
Merck & Co Inc 25
N-Gene Research Laboratories Inc 25
Nissan Chemical Industries Ltd 26
…Continued

ACCESS REPORT @ https://www.wiseguyreports.com/reports/1705797-atrial-fibrillation-pipeline-review-h2-2017

Get in touch:
LinkedIn: www.linkedin.com/company/4828928
Twitter: https://twitter.com/WiseGuyReports
Facebook: https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts

Norah Trent
wiseguyreports
+1 646 845 9349 / +44 208 133 9349
email us here


Source: EIN Presswire

Heart Failure Therapeutic and Drug Pipeline Review H2

Heart Failure Therapeutic Pipeline Market Review, H2 2017

PUNE, INDIA, August 14, 2017 /EINPresswire.com/ — Pune, India, 14th August 2017: WiseGuyReports announced addition of new report, titled “Congestive Heart Failure (Heart Failure) – Pipeline Review, H2 2017”.

Summary
Heart failure is also known as congestive heart failure (CHF). CHF is a condition in which the heart is no longer able to pump out enough oxygen-rich blood. Symptoms include cough, fatigue, weakness, faintness, loss of appetite, swollen (enlarged) liver or abdomen, swollen feet and ankles and weight gain. The predisposing factors include high blood pressure, diabetes, sleep apnea, alcohol use and irregular heartbeats. Treatment includes surgery, vasodilator, beta blockers and diuretics.

GET SAMPLE REPORT @ https://www.wiseguyreports.com/sample-request/1705798-congestive-heart-failure-heart-failure-pipeline-review-h2-2017

Report Highlights
Pharmaceutical and Healthcare latest pipeline guide Congestive Heart Failure (Heart Failure) – Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Congestive Heart Failure (Heart Failure) (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Congestive Heart Failure (Heart Failure) (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Congestive Heart Failure (Heart Failure) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 19, 27, 17, 2, 43, 11 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 19 and 8 molecules, respectively.

Congestive Heart Failure (Heart Failure) (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope
– The pipeline guide provides a snapshot of the global therapeutic landscape of Congestive Heart Failure (Heart Failure) (Cardiovascular).
– The pipeline guide reviews pipeline therapeutics for Congestive Heart Failure (Heart Failure) (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
– The pipeline guide reviews key companies involved in Congestive Heart Failure (Heart Failure) (Cardiovascular) therapeutics and enlists all their major and minor projects.
– The pipeline guide evaluates Congestive Heart Failure (Heart Failure) (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
– The pipeline guide reviews latest news related to pipeline therapeutics for Congestive Heart Failure (Heart Failure) (Cardiovascular)

Reasons to buy
– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
– Find and recognize significant and varied types of therapeutics under development for Congestive Heart Failure (Heart Failure) (Cardiovascular).
– Classify potential new clients or partners in the target demographic.
– Develop tactical initiatives by understanding the focus areas of leading companies.
– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
– Formulate corrective measures for pipeline projects by understanding Congestive Heart Failure (Heart Failure) (Cardiovascular) pipeline depth and focus of Indication therapeutics.
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Content: Key Points
Table of Contents 2
Introduction 5
Congestive Heart Failure (Heart Failure) – Overview 6
Congestive Heart Failure (Heart Failure) – Therapeutics Development 7
Congestive Heart Failure (Heart Failure) – Therapeutics Assessment 26
Congestive Heart Failure (Heart Failure) – Companies Involved in Therapeutics Development 40
Congestive Heart Failure (Heart Failure) – Drug Profiles 75
Congestive Heart Failure (Heart Failure) – Dormant Projects 360
Congestive Heart Failure (Heart Failure) – Discontinued Products 366
Congestive Heart Failure (Heart Failure) – Product Development Milestones 368
…Continued

ACCESS REPORT @ https://www.wiseguyreports.com/reports/1705798-congestive-heart-failure-heart-failure-pipeline-review-h2-2017

Get in touch:
LinkedIn: www.linkedin.com/company/4828928
Twitter: https://twitter.com/WiseGuyReports
Facebook: https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts

Norah Trent
wiseguyreports
+1 646 845 9349 / +44 208 133 9349
email us here


Source: EIN Presswire

Global Myocarditis Drugs and Companies Pipeline Review H2 2017

Myocarditis Treatment Pipeline Review H2 2017

PUNE, INDIA, August 14, 2017 /EINPresswire.com/ — Pune, India, 14thAugust 2017: WiseGuyReports announced addition of new report, titled “Myocarditis – Pipeline Review, H2 2017”.

Summary
Myocarditis is inflammation of the heart muscle. Myocarditis is an uncommon disorder that is usually caused by viral, bacterial, or fungal infections that reach the heart. Symptoms include chest pain, rapid or abnormal heartbeat, shortness of breath, at rest or during physical activity, fluid retention with swelling of legs, ankles and feet and fatigue. Treatment includes antibiotics, anti-inflammatory medicines to reduce swelling and diuretics to remove excess water from the body.

GET SAMPLE REPORT @ https://www.wiseguyreports.com/sample-request/1705799-myocarditis-pipeline-review-h2-2017

Report Highlights
Pharmaceutical and Healthcare latest pipeline guide Myocarditis – Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Myocarditis (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Myocarditis (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Myocarditis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase I and Preclinical stages are 1 and 3 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 3 molecules, respectively.

Myocarditis (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope
– The pipeline guide provides a snapshot of the global therapeutic landscape of Myocarditis (Cardiovascular).
– The pipeline guide reviews pipeline therapeutics for Myocarditis (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
– The pipeline guide reviews key companies involved in Myocarditis (Cardiovascular) therapeutics and enlists all their major and minor projects.
– The pipeline guide evaluates Myocarditis (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
– The pipeline guide reviews latest news related to pipeline therapeutics for Myocarditis (Cardiovascular)

Reasons to buy
– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
– Find and recognize significant and varied types of therapeutics under development for Myocarditis (Cardiovascular).
– Classify potential new clients or partners in the target demographic.
– Develop tactical initiatives by understanding the focus areas of leading companies.
– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
– Formulate corrective measures for pipeline projects by understanding Myocarditis (Cardiovascular) pipeline depth and focus of Indication therapeutics.
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Content: Key Points
List of Tables
List of Figures
Introduction
Myocarditis – Overview
Myocarditis – Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Myocarditis – Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Myocarditis – Companies Involved in Therapeutics Development
CEL-SCI Corp
GlaxoSmithKline Plc
Swedish Orphan Biovitrum AB
Myocarditis – Drug Profiles
anakinra – Drug Profile
Product Description
…Continued

ACCESS REPORT @ https://www.wiseguyreports.com/reports/1705799-myocarditis-pipeline-review-h2-2017

Get in touch:
LinkedIn: www.linkedin.com/company/4828928
Twitter: https://twitter.com/WiseGuyReports
Facebook: https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts

Norah Trent
wiseguyreports
+1 646 845 9349 / +44 208 133 9349
email us here


Source: EIN Presswire

Market Overview of Liver Cancer pipeline Landscape

Liver Cancer Therapeutics strategies and Product Pipeline Review 2017

PUNE, INDIA, August 14, 2017 /EINPresswire.com/ — Pune, India, 14thAugust 2017: WiseGuyReports announced addition of new report, titled “Frontier Pharma: Liver Cancer – Identifying and Commercializing First-in-Class Innovation”.

Summary
Globally, liver cancer is the sixth most common cancer, but its poor prognosis makes it the second leading cause of cancer-related death (Globocan, 2012). Currently, the range of therapies is limited; the market consisted entirely of chemotherapies for many years, and only recently have targeted therapies begun to emerge.

GET SAMPLE REPORT @ https://www.wiseguyreports.com/sample-request/33621-frontier-pharma-liver-cancer-identifying-and-commercializing-first-in-class-innovation

The liver cancer market is segmented in terms of its needs. Early-stage patients have access to curative therapies such as surgical resection, and therefore have a relatively positive outlook. However, at at the opposite end of the spectrum patients that are diagnosed in later stages – who represent the majority of the patient population – are not eligible for surgery, and have a very poor prognosis in spite of the approvals of targeted therapies such as Nexavar (sorafenib) and Stivarga (regorafenib).

In stark contrast to the relatively limited market landscape, which contains just 86 products, the liver cancer pipeline is large, diverse and highly innovative. The pipeline has 423 products in active development, with diversity of both molecule type and mechanism of action. Of these, 122 are first-in-class, and act on 109 distinct first-in-class molecular targets. These products span a very wide range of molecular target types including cancer immunotherapies, receptor tyrosine kinases, targeted cytotoxic agents and kinase inhibitors, far exceeding the scope of products present in the chemotherapy-dominated market.

Scope
– The 423 products in active development, of which 122 are first-in-class and therefore act on completely novel targets, far exceed the scope of the current market. How will pipeline innovation affect the future liver cancer market?
– There are 109 distinct first-in-class molecular targets currently being studied. Which of these hold the greatest potential to improve future disease treatment with regard to their molecular target?
– The majority of first-in-class products in development are cancer immunotherapies. Which of these are the most promising, and how does the ratio of first-in-class targets to first-in-class products differ by stage of development and molecular target class?
– A significant number of first-in-class products have been identified with some prior involvement in deals. How do deal frequency and value compare between target families and molecule types, and which first-in-class programs have not yet been involved in a licensing or co-development deal?

Reasons to buy
– Understand the current clinical and commercial landscape. The report includes a comprehensive study of disease pathogenesis, diagnosis, prognosis and the treatment options available.
– Visualize the composition of the liver cancer market in terms of dominant molecule types and targets, highlighting what the current unmet needs are and how they can be addressed. This knowledge allows a competitive understanding of gaps in the market.
– Analyze the liver cancer pipeline and stratify by stage of development, molecule type and molecular target. There are strong signs in the pipeline that the industry is seeking novel approaches to treating liver cancer subtypes such as hepatocellular carcinoma and cholangiocarcinoma.
– Assess the therapeutic potential of first-in-class targets. Using a proprietary molecular target matrix, first-in-class products have been assessed and ranked according to clinical potential.
– Identify commercial opportunities in the liver cancer deals landscape by analyzing trends in licensing and co-development deals, and producing a list of first-in-class therapies with no prior involvement in licensing or co-development deals.

Table of Content: Key Points

1 Table of Contents 2
1.1 List of Tables 3
1.2 List of Figures 3
2 Executive Summary 4
2.1 High Unmet Need and a Limited Number of Marketed Options 4
2.2 Large, Diverse and Highly Innovative Pipeline 4
2.3 Active Deals Landscape Reflects the Dynamic Pipeline 4
3 The Case for Innovation 5
3.1 Growing Opportunities for Biologic Products 6
3.2 Diversification of Molecular Targets 6
3.3 Innovative First-in-Class Product Developments Remain Attractive 7
3.4 Regulatory and Reimbursement Policy Shifts Favor First-in-Class Product Innovation 7
3.5 Sustained Innovation 8
3.6 GBI Research Report Guidance 8
4 Clinical and Commercial Landscape 9
4.1 Disease Overview 9
4.2 Symptoms 9
4.3 Diagnosis 10
4.3.1 Clinical Presentation 10
4.3.2 Alpha-Fetoprotein 10
4.3.3 Diagnostic Imaging and Scans 10
4.3.4 Screening 10
4.3.5 Biopsy 11
4.3.6 Staging, Classification and Prognosis 11
4.4 Epidemiology and Etiology 11
4.5 Pathophysiology 13
4.6 Risk Factors and Co-Morbidities 17
4.7 Treatment Options 17
4.8 Treatment Algorithm 18
4.9 Overview of Marketed Products for Liver Cancer 19
4.9.1 Innovative Products in the Liver Cancer Market 20
4.9.2 Unmet Needs 21
5 Assessment of Pipeline Product Innovation 22
…Continued

ACCESS REPORT @ https://www.wiseguyreports.com/reports/33621-frontier-pharma-liver-cancer-identifying-and-commercializing-first-in-class-innovation

Get in touch:
LinkedIn: www.linkedin.com/company/4828928
Twitter: https://twitter.com/WiseGuyReports
Facebook: https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts

Norah Trent
wiseguyreports
+1 646 845 9349 / +44 208 133 9349
email us here


Source: EIN Presswire

Healthcare Buildings (Construction) in Egypt Market (By Segment, Key Players and Applications) and Forecasts To 2021

Healthcare Buildings (Construction) in Egypt Market Share, Opportunities, Segmentation and Forecast to 2021

PUNE, INDIA, August 14, 2017 /EINPresswire.com/ — Pune, India, 14th August 2017: WiseGuyReports announced addition of new report, titled “Healthcare Buildings (Construction) in Egypt: Market Analytics by Category & Cost Type to 2021”.

Synopsis
"Healthcare Buildings (Construction) in Egypt: Market Analytics by Category & Cost Type to 2021" contains historic and forecast market data for the healthcare buildings category in Egypt, it also provides detailed breakdown of the data by construction activity (new construction, repair and maintenance, refurbishment and demolition) and by cost type (construction materials, construction equipment and construction services).

GET SAMPLE REPORT @ https://www.wiseguyreports.com/sample-request/1697766-healthcare-buildings-construction-in-egypt-market-analytics-by-category-cost-type

Summary
The healthcare buildings category covers the development of facilities that are specifically designed to house healthcare service providers. The category includes, but is not limited to, hospitals, clinics, surgeries and laboratories.

The Egyptian healthcare buildings construction category continued to increase in the review period with a value of EGPxx.xx million (US$xx.xx million) in 2016 and increased at a rate of xx.xx% over 2015. The market recorded a CAGR of xx.xx% from 2012 through 2016.

"Healthcare Buildings (Construction) in Egypt: Market Analytics by Category & Cost Type to 2021"' provides a top-level overview and detailed insight into the operating environment of the healthcare buildings market in Egypt. It is an essential tool for companies active across the Egypt construction value chain and for new players considering to enter the market.

Scope
• A top level overview of the healthcare buildings construction category in Egypt.
• Historic data provided from 2012 through 2016 and forecast from 2017 through 2021.
• A detailed breakdown of the data by construction activity (new construction, repair and maintenance, refurbishment and demolition) and by cost type (construction materials, construction equipment & construction services) across the healthcare buildings market.

Reasons to Buy
• Provides a top level understanding of the Healthcare Buildings construction in Egypt.
• Helps you understand the market performance by construction activity (new construction, repair and maintenance, refurbishment and demolition) and construction cost type (construction materials, construction equipment & construction services).
• Allows you to plan future business decisions using the forecast figures given.
• The broad but detailed perspective will help all the players in the construction activity to understand and succeed in the challenging construction market.

Table of Content: Key Points

1 Introduction
1.1 What is this Report About?
1.2 Definitions
1.3 CAGR Definition and Calculation
2 Overall Healthcare Buildings: Market Analysis
2.1 Overall Healthcare Buildings Output Value, 2012 – 2016
2.2 Overall Healthcare Buildings Output Value Forecast, 2017 – 2021
2.3 Overall Healthcare Buildings Output, by Cost Type
2.3.1 Overall Healthcare Buildings Output, by Cost Type, 2012 – 2016
2.3.2 Overall Healthcare Buildings Output Forecast, by Cost Type, 2017 – 2021
3 Healthcare Buildings Output: Analysis by Category
3.1 New Construction Output Value, 2012 – 2016
3.2 New Construction Output Value Forecast, 2017 – 2021
3.3 New Construction Output Value by Cost Type
3.3.1 New Construction Output, by Cost type, 2012 – 2016
3.3.2 New Construction Output Forecast, by Cost Type, 2017 – 2021
3.4 Repair & Maintenance Output Value, 2012 – 2016
3.5 Repair & Maintenance Output value Forecast, 2017 – 2021
3.6 Repair & Maintenance Output, by Cost Type
3.6.1 Repair & Maintenance Output, by Cost type, 2012 – 2016
3.6.2 Repair & Maintenance Output Forecast, by Cost Type, 2017 – 2021
3.7 Refurbishment Construction Output Value, 2012 – 2016
3.8 Refurbishment Construction Output Value Forecast, 2017 – 2021
3.9 Refurbishment Construction Output, by Cost Type
3.9.1 Refurbishment Construction Output, by Cost type, 2012 – 2016
3.9.2 Refurbishment Construction Output Forecast, by Cost type, 2017 – 2021
3.1 Demolition Construction Output Value, 2012 – 2016
3.11 Demolition Construction Output Value Forecast, 2017 – 2021
3.12 Demolition Construction Output, by Cost Type
3.12.1 Demolition Construction Output, by Cost type, 2012 – 2016
3.12.2 Demolition Construction Output Forecast, by Cost type, 2017 – 2021
4 Appendix
…Continued

ACCESS REPORT @ https://www.wiseguyreports.com/reports/1697766-healthcare-buildings-construction-in-egypt-market-analytics-by-category-cost-type

Get in touch:
LinkedIn: www.linkedin.com/company/4828928
Twitter: https://twitter.com/WiseGuyReports
Facebook: https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts

Norah Trent
wiseguyreports
+1 646 845 9349 / +44 208 133 9349
email us here


Source: EIN Presswire

High Speed Steel Market 2017 Global Share, Trend, Segmentation and Forecast to 2022

Wiseguyreports.Com Added New Market Research Report On -“Global High Speed Steel Market 2017 Top Manufacturers, Growth and Demand Forecast to 2022”.

PUNE, INDIA, August 14, 2017 /EINPresswire.com/ —

Global High Speed Steel Market

Description

This report studies High Speed Steel in Global Market, especially in North America, China, Europe, Southeast Asia, Japan and India, with production, revenue, consumption, import and export in these regions, from 2012 to 2016, and forecast to 2022.

This report focuses on top manufacturers in global market, with production, price, revenue and market share for each manufacturer, covering 
EraSteel 
Bohler 
Carpenter 
Hitachi 
Nachi 
Crucible Industries 
Graphite India Limited 
DSS 
Sandvik 
Griggs 
Tiangong International 
HEYE Special Steel 
FEIDA 
Fuda 
Bewise 
Jinggong 
Zhongqiang Roll

 
Get sample Report @  https://www.wiseguyreports.com/sample-request/1688539-global-high-speed-steel-market-professional-survey-report-2017

 
On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into 
T Type 
M Type 
Other Types

By Application, the market can be split into 
Metal Cutting Tools 
Cold Working Die 
Roll 
Others

By Regions, this report covers (we can add the regions/countries as you want) 
North America 
China 
Europe 
Southeast Asia 
Japan 
India

Complete Report Details @ https://www.wiseguyreports.com/reports/1688539-global-high-speed-steel-market-professional-survey-report-2017

 
Table of Contents -Major Key Points

Global High Speed Steel Market Professional Survey Report 2017 
1 Industry Overview of High Speed Steel 
1.1 Definition and Specifications of High Speed Steel 
1.1.1 Definition of High Speed Steel 
1.1.2 Specifications of High Speed Steel 
1.2 Classification of High Speed Steel 
1.2.1 T Type 
1.2.2 M Type 
1.2.3 Other Types 
1.3 Applications of High Speed Steel 
1.3.1 Metal Cutting Tools 
1.3.2 Cold Working Die 
1.3.3 Roll 
1.3.4 Others 
1.4 Market Segment by Regions 
1.4.1 North America 
1.4.2 China 
1.4.3 Europe 
1.4.4 Southeast Asia 
1.4.5 Japan 
1.4.6 India

8 Major Manufacturers Analysis of High Speed Steel 
8.1 EraSteel 
8.1.1 Company Profile 
8.1.2 Product Picture and Specifications 
8.1.2.1 Product A 
8.1.2.2 Product B 
8.1.3 EraSteel 2016 High Speed Steel Sales, Ex-factory Price, Revenue, Gross Margin Analysis 
8.1.4 EraSteel 2016 High Speed Steel Business Region Distribution Analysis 
8.2 Bohler 
8.2.1 Company Profile 
8.2.2 Product Picture and Specifications 
8.2.2.1 Product A 
8.2.2.2 Product B 
8.2.3 Bohler 2016 High Speed Steel Sales, Ex-factory Price, Revenue, Gross Margin Analysis 
8.2.4 Bohler 2016 High Speed Steel Business Region Distribution Analysis 
8.3 Carpenter 
8.3.1 Company Profile 
8.3.2 Product Picture and Specifications 
8.3.2.1 Product A 
8.3.2.2 Product B 
8.3.3 Carpenter 2016 High Speed Steel Sales, Ex-factory Price, Revenue, Gross Margin Analysis 
8.3.4 Carpenter 2016 High Speed Steel Business Region Distribution Analysis 
8.4 Hitachi 
8.4.1 Company Profile 
8.4.2 Product Picture and Specifications 
8.4.2.1 Product A 
8.4.2.2 Product B 
8.4.3 Hitachi 2016 High Speed Steel Sales, Ex-factory Price, Revenue, Gross Margin Analysis 
8.4.4 Hitachi 2016 High Speed Steel Business Region Distribution Analysis 
8.5 Nachi 
8.5.1 Company Profile 
8.5.2 Product Picture and Specifications 
8.5.2.1 Product A 
8.5.2.2 Product B 
8.5.3 Nachi 2016 High Speed Steel Sales, Ex-factory Price, Revenue, Gross Margin Analysis 
8.5.4 Nachi 2016 High Speed Steel Business Region Distribution Analysis 
8.6 Crucible Industries 
8.6.1 Company Profile 
8.6.2 Product Picture and Specifications 
8.6.2.1 Product A 
8.6.2.2 Product B 
8.6.3 Crucible Industries 2016 High Speed Steel Sales, Ex-factory Price, Revenue, Gross Margin Analysis 
8.6.4 Crucible Industries 2016 High Speed Steel Business Region Distribution Analysis 
8.7 Graphite India Limited 
8.7.1 Company Profile 
8.7.2 Product Picture and Specifications 
8.7.2.1 Product A 
8.7.2.2 Product B 
8.7.3 Graphite India Limited 2016 High Speed Steel Sales, Ex-factory Price, Revenue, Gross Margin Analysis 
8.7.4 Graphite India Limited 2016 High Speed Steel Business Region Distribution Analysis 
8.8 DSS 
8.8.1 Company Profile 
8.8.2 Product Picture and Specifications 
8.8.2.1 Product A 
8.8.2.2 Product B 
8.8.3 DSS 2016 High Speed Steel Sales, Ex-factory Price, Revenue, Gross Margin Analysis 
8.8.4 DSS 2016 High Speed Steel Business Region Distribution Analysis 
8.9 Sandvik 
8.9.1 Company Profile 
8.9.2 Product Picture and Specifications 
8.9.2.1 Product A 
8.9.2.2 Product B 
8.9.3 Sandvik 2016 High Speed Steel Sales, Ex-factory Price, Revenue, Gross Margin Analysis 
8.9.4 Sandvik 2016 High Speed Steel Business Region Distribution Analysis 
8.10 Griggs 
8.10.1 Company Profile 
8.10.2 Product Picture and Specifications 
8.10.2.1 Product A 
8.10.2.2 Product B 
8.10.3 Griggs 2016 High Speed Steel Sales, Ex-factory Price, Revenue, Gross Margin Analysis 
8.10.4 Griggs 2016 High Speed Steel Business Region Distribution Analysis 
8.11 Tiangong International 
8.12 HEYE Special Steel 
8.13 FEIDA 
8.14 Fuda 
8.15 Bewise 
8.16 Jinggong 
8.17 Zhongqiang Roll

………..CONTINUED

 
Buy Now@ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=1688539

Norah Trent
WiseGuy Research Consultants Pvt. Ltd.
+1 646 845 9349 / +44 208 133 9349
email us here


Source: EIN Presswire

Quick Update & Your E-Ticket for Ophthalmic Drugs 2017

LONDON, UNITED KINGDOM, August 14, 2017 /EINPresswire.com/ — We hope you're enjoying some time off this Summer! I just wanted to quickly update you about the Ophthalmic Drugs conference taking place this November, and how you cannot afford to miss out!

Ophthalmic Drugs has gained some great traction throughout these few months, with an incredible representation from our pharma industry experts, who will help you tackle every possible obstacle you may face through real-life case studies. Gain insight into current trends in novel technology being used for preclinical and clinical trials.

Companies Attending: Santen Inc, Shire, Novartis, Roche, NightstaRx, Aerie Pharmaceuticals, Bayer, Envisia Therapeutics, Boehringer Ingelheim, Oxford BioMedica, Novaliq GmbH, Alimera Sciences, Aptar Pharma and PharmaMedic Consultancy Ltd.

Presenting Case Studies & Topics Within: Novel approaches to the treatment of ocular diseases such as presbyopia and glaucoma, combating challenges in drug release and delivery, regulatory considerations involving new technologies and patient reported outcomes.

The finalised agenda is now available online: www.ophthalmicdrugs.com/prl4

How Can You Benefit?

– 16+ Peer-led Sessions
– 15+ Hrs of Highly Interactive Content
– An Audience of Ophthalmic Experts & Innovators Under 1 Roof

Learn. Tackle. Network.

Claim your e-ticket online, and save £300 (limited time only) www.ophthalmicdrugs.com/prl4

Check out the finalised agenda here: http://www.ophthalmicdrugs.com/prl4

SMi is Proud to Present the Launch of…
Ophthalmic Drugs
Date: 28th – 29th November 2017
Location: London, UK
Website: http://www.ophthalmicdrugs.com/prl4

Sponsors:
– EXPERIMENTICA
– LEICA MICROSYSTEMS

—end—

Contact Information:

For all media inquiries contact Pavan Solanki on Tel: +44 (0)20 7827 6048 / Email: psolanki@smi-online.co.uk

About SMi Group:

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk

Pav Solanki
SMi Group
2078276048
email us here


Source: EIN Presswire

Virtual Digital Assistants(VDA)Market 2017 Global Share, Trend, Segmentation and Forecast to 2022

Wiseguyreports.Com Added New Market Research Report On -“Global Virtual Digital Assistants(VDA)Market 2017 Top Manufacturers, and Demand Forecast to 2022”.

PUNE, INDIA, August 14, 2017 /EINPresswire.com/ —

Global Virtual Digital Assistants(VDA)Market

Description

This report studies the global Virtual Digital Assistants(VDA)Market, analyzes and researches the Virtual Digital Assistants(VDA) development status and forecast in United States, EU, Japan, China, India and Southeast Asia. This report focuses on the top players in global market, like 
Introduction 
[24]7 Inc. 
Amazon 
ai 
Apple 
Applied Voice & Speech Technologies 
Artificial Solutions 
Baidu 
Botego 
CodeBaby 
CogniCor 
Creative Virtual 
CX Company 
EasilyDo 
Facebook 
Google 
IBM 
Inbenta Technologies 
Interactions 
IPsoft 
Ivee 
Jibo 
Living Actor (Cantoche) 
Microsoft 
MindMeld 
Next IT 
Nuance 
Openstream 
Samsung 
Sensory

 

Get sample Report @  https://www.wiseguyreports.com/sample-request/1749445-global-virtual-digital-assistants-vda-market-size-status-and-forecast-2022

 

Market segment by Regions/Countries, this report covers 
United States 
EU 
Japan 
China 
India 
Southeast Asia

Market segment by Type, Virtual Digital Assistants(VDA) can be split into 
Consumer VDAs 
Enterprise VDA 
Other

Market segment by Application, Virtual Digital Assistants(VDA) can be split into 
Smart Home and the Internet of Things 
Automobiles 
Other

Complete Report Details @ https://www.wiseguyreports.com/reports/1749445-global-virtual-digital-assistants-vda-market-size-status-and-forecast-2022

 

Table of Contents -Major Key Points

Global Virtual Digital Assistants(VDA) Market Size, Status and Forecast 2022 
1 Industry Overview of Virtual Digital Assistants(VDA) 
1.1 Virtual Digital Assistants(VDA) Market Overview 
1.1.1 Virtual Digital Assistants(VDA) Product Scope 
1.1.2 Market Status and Outlook 
1.2 Global Virtual Digital Assistants(VDA) Market Size and Analysis by Regions 
1.2.1 United States 
1.2.2 EU 
1.2.3 Japan 
1.2.4 China 
1.2.5 India 
1.2.6 Southeast Asia 
1.3 Virtual Digital Assistants(VDA) Market by Type 
1.3.1 Consumer VDAs 
1.3.2 Enterprise VDA 
1.3.3 Other 
1.4 Virtual Digital Assistants(VDA) Market by End Users/Application 
1.4.1 Smart Home and the Internet of Things 
1.4.2 Automobiles 
1.4.3 Other

3 Company (Top Players) Profiles 
3.1 Introduction 
3.1.1 Company Profile 
3.1.2 Main Business/Business Overview 
3.1.3 Products, Services and Solutions 
3.1.4 Virtual Digital Assistants(VDA) Revenue (Value) (2012-2017) 
3.1.5 Recent Developments 
3.2 [24]7 Inc. 
3.2.1 Company Profile 
3.2.2 Main Business/Business Overview 
3.2.3 Products, Services and Solutions 
3.2.4 Virtual Digital Assistants(VDA) Revenue (Value) (2012-2017) 
3.2.5 Recent Developments 
3.3 Amazon 
3.3.1 Company Profile 
3.3.2 Main Business/Business Overview 
3.3.3 Products, Services and Solutions 
3.3.4 Virtual Digital Assistants(VDA) Revenue (Value) (2012-2017) 
3.3.5 Recent Developments 
3.4 ai 
3.4.1 Company Profile 
3.4.2 Main Business/Business Overview 
3.4.3 Products, Services and Solutions 
3.4.4 Virtual Digital Assistants(VDA) Revenue (Value) (2012-2017) 
3.4.5 Recent Developments 
3.5 Apple 
3.5.1 Company Profile 
3.5.2 Main Business/Business Overview 
3.5.3 Products, Services and Solutions 
3.5.4 Virtual Digital Assistants(VDA) Revenue (Value) (2012-2017) 
3.5.5 Recent Developments 
3.6 Applied Voice & Speech Technologies 
3.6.1 Company Profile 
3.6.2 Main Business/Business Overview 
3.6.3 Products, Services and Solutions 
3.6.4 Virtual Digital Assistants(VDA) Revenue (Value) (2012-2017) 
3.6.5 Recent Developments 
3.7 Artificial Solutions 
3.7.1 Company Profile 
3.7.2 Main Business/Business Overview 
3.7.3 Products, Services and Solutions 
3.7.4 Virtual Digital Assistants(VDA) Revenue (Value) (2012-2017) 
3.7.5 Recent Developments 
3.8 Baidu 
3.8.1 Company Profile 
3.8.2 Main Business/Business Overview 
3.8.3 Products, Services and Solutions 
3.8.4 Virtual Digital Assistants(VDA) Revenue (Value) (2012-2017) 
3.8.5 Recent Developments 
3.9 Botego 
3.9.1 Company Profile 
3.9.2 Main Business/Business Overview 
3.9.3 Products, Services and Solutions 
3.9.4 Virtual Digital Assistants(VDA) Revenue (Value) (2012-2017) 
3.9.5 Recent Developments 
3.10 CodeBaby 
3.10.1 Company Profile 
3.10.2 Main Business/Business Overview 
3.10.3 Products, Services and Solutions 
3.10.4 Virtual Digital Assistants(VDA) Revenue (Value) (2012-2017) 
3.10.5 Recent Developments 
3.11 CogniCor 
3.12 Creative Virtual 
3.13 CX Company 
3.14 EasilyDo 
3.15 Facebook 
3.16 Google 
3.17 IBM 
3.18 Inbenta Technologies 
3.19 Interactions 
3.20 IPsoft 
3.21 Ivee 
3.22 Jibo 
3.23 Living Actor (Cantoche) 
3.24 Microsoft 
3.25 MindMeld 
3.26 Next IT 
3.27 Nuance 
3.28 Openstream 
3.29 Samsung 
3.30 Sensory

………..CONTINUED

 

Buy Now@ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=1749445

Norah Trent
WiseGuy Research Consultants Pvt. Ltd.
+1 646 845 9349 / +44 208 133 9349
email us here


Source: EIN Presswire